SPECT/CT Combined With Fluorescence Imaging Detects Micrometastases

Researchers in The Netherlands have demonstrated that combining SPECT/CT and fluorescence imaging could help surgeons differentiate tumor tissue from normal tissue.

The research is detailed in the featured basic science article of the May 2017 issue of The Journal of Nuclear Medicine.

New Strategy To Develop An Improved Colorectal Cancer Test
Colorectal cancer is the abnormal growth in large intestines. A recent research finds a promising step to pave way for developing an improved diagnostic test.

‘Micrometastases of colorectal carcinoma can be detected specifically with fluorescence imaging and SPECT/CT before they become visible with the naked eye.’

Tweet it Now

The study focused on colorectal cancer (CRC) that metastasized beyond the primary tumor. CRC is the second most common cancer in men and the third most common in women. According to the American Cancer Society, more than 50,000 people in the U.S. are expected to die from the disease in 2017.

"This study shows that micrometastases of colorectal carcinoma can be detected specifically with fluorescence imaging and SPECT/CT before they become visible with the naked eye," says Marlène C.H. Hekman of the Department of Radiology and Nuclear Medicine at Radboudumc, Nijmegen, The Netherlands.

The researchers used a mouse model to show that pulmonary micrometastases of CRC can be identified with labetuzumab, labeled with both a near-infrared fluorescent dye (IRDye800CW) and a radioactive label (Indium-111). Labetuzumab, developed by Immunomedics, Inc., is an antibody that targets carcinoembryonic antigen (CEA), which is overexpressed in approximately 95 percent of CRC cases. Specifically, it is an investigational anti-CEA-related cell adhesion molecule 5 (CEACAM5) antibody.

New Zealand�s Young Adults At Risk For Colorectal Cancer
In New Zealand, rectal cancer is on the rise among adults aged below 50.

Sub-millimeter pulmonary tumor colonies were visualized with both micro-SPECT and fluorescence imaging from the first week of tumor growth. In addition, the study demonstrated that dual-modality imaging can be used to guide resection of tumor lesions.

"Complete tumor resection is crucial for optimal prognosis of cancer patients," Hekman explains. "Intraoperative imaging can help the surgeon to resect residual disease completely. To be of optimal benefit in the operating room, dual-modality imaging should be able to detect very small tumor lesions that might otherwise be missed."

Many Factors Influence a Patient's Intent to Get Colorectal Cancer Screening
Women often will say, in focus groups or interviews or surveys, 'Colorectal Cancer is a man's disease,' when, in fact, it equally impacts men and women.

She points out, "The study shows that SPECT and fluorescence dual-modality imaging after injection of Indium-111-DTPA-labetuzumab-IRDye800CW is able to detect tiny CEA-expressing nodules. This strategy can also be used for other types of cancer, when a different tumor-targeting antibody is used. It is, therefore, relevant for a broad range of cancer types. Since our findings may be translated to a broad range of tumor types, dual-modality imaging may revolutionize oncological surgery and improve the prognosis of cancer patients."

Source-Eurekalert

Adults With Disabilities Do Not Receive Routine Screenings for Colorectal Cancer
Those with vision impairment, intellectual disability or spinal cord injury less likely to be screened.